Escient Pharmaceuticals News and Activities

Escient Pharmaceuticals is owned by Incyte.

Incyte is one of the...

• Forbes Global 2000 (#1409);
• Fortune 500 (#664);
• Russell 3000;
• S&P 500;
• TOB Iconic 10,000.

Incyte is a company listed under the stock ticker INCY (US).

Incyte has a direct presence in 3 countries.

Incyte has 4 subsidiaries including Escient Pharmaceuticals, Incyte Canada and Incyte Europe.

They are in:

• Biotechnology80%
• Pharmaceuticals20%

Acquisition, funding and merger involving Incyte.

• Incyte has announced the acquisition of Star Therapeutics  (posted on June 9 2026).
• Vor Biopharma and Incyte have announced they will merge  (posted on June 30 2025)..

View the org chart displaying its 3 main executives

Most searched biographies at Escient Pharmaceuticals

• Joshua Grass, Chief Executive Officer and Director
• Christian Weyer, Chief Medical Officer
• David Houck, Vice President of Chemistry, Manufacturing & Controls

Popular executive movements at Incyte

• Suketu Upadhyay will join the company as Chief Financial Officer on May 4, 2026  (posted on April 28 2026).
• Thomas Tray, Principal Financial Officer, will leave the company on May 4, 2026  (posted on April 28 2026).
• Sri Ghatta has joined the company as Senior Director, Clinical Research  (posted on April 9 2026).

Click here to view some more movements at Incyte

Create your alert
to follow the executive moves at Escient Pharmaceuticals.

Incyte has 2,425 competitors including Lonza (Switzerland), Vertex Pharmaceuticals (United States (USA)) and Eurofins (Luxembourg).

Popular M&A news in Biotechnology

• Chemomab and Scipher Medicine have announced they will merge  (posted on July 13 2026)..
• Apnimed has filed its IPO. Its stock ticker will be APMD. (posted on July 13 2026).
• The new name of EG 427 is Cyllene Therapeutics. (posted on July 10 2026).

Popular contacts in Biotechnology

• Jakob Uszkoreit - Co-Founder and Chief Executive Officer at Inceptive
• Jan Van de Winkel - President and Chief Executive Officer at Genmab
• Robert Gould - Board Member at Fulcrum Therapeutics

Learn more about the Biotechnology industry

Press releases by Escient Pharmaceuticals

• Press Releases - Escient pharmaceuticals
• Escient Pharmaceuticals Launches with $40 Million Series A Financing to Advance First-in-Class G Protein-Coupled Receptor (GPCR)-Targeted Drugs to Address Serious, Unserved Medical Needs | Business Wire
• Media - Escient pharmaceuticals
• Press Releases - Escient pharmaceuticals

Social media about Escient Pharmaceuticals

• Escient Pharmaceuticals on Wikipedia, Google News & Yahoo Finance
• Escient Pharmaceuticals on LinkedIn, X (Twitter) & YouTube